NBI-921352 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Conditions
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Trial Timeline
Jan 31, 2022 → Mar 17, 2023
NCT ID
NCT04873869About NBI-921352 + Placebo
NBI-921352 + Placebo is a phase 2 stage product being developed by Neurocrine Biosciences for SCN8A Developmental and Epileptic Encephalopathy Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT04873869. Target conditions include SCN8A Developmental and Epileptic Encephalopathy Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04873869 | Phase 2 | Terminated |
| NCT05159908 | Phase 2 | Completed |
Competing Products
1 competing product in SCN8A Developmental and Epileptic Encephalopathy Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NBI-921352 | Neurocrine Biosciences | Phase 2 | 49 |